Tisztelt látogatónk!

Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21

Current Group expectations for FY/21

Based on the current status of the Group"s financial planning process and assuming that the current burdens and constraints caused by the COVID-19 pandemic only begin to recede in the second half of the year, Fresenius targets healthy sales growth¹ and at least broadly stable net income² year over year in FY/21. The FY/21 earnings are, hence, expected to be very meaningfully impacted by COVID-19 effects. In particular, as reported today by Fresenius Medical Care, the significant acceleration of mortality among dialysis patients due to COVID-19 is expected to have a material impact on Fresenius Medical Care"s results and hence on Fresenius Group"s net income² growth.

Group medium-term targets

The current information and assumptions do not trigger a revision of Fresenius" medium-term growth targets, which were set before the COVID-19 pandemic emerged.

Fresenius will announce more detailed FY/21 financial guidance with the release of its FY/20 results on February 23, 2021.

¹ in constant currency
² Net income attributable to shareholders of Fresenius SE & Co. KGaA; in constant currency; before any special items and any one-time expenses related to likely efficiency and cost saving programs

For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.

Fresenius SE & Co. KGaA,

represented by Fresenius Management SE,

The Management Board

Bad Homburg v.d.H., February 1, 2021

----------------------------------------

Contact:

Markus Georgi

Senior Vice President Investor Relations & Sustainability

T: +49 (0) 6172 608-2485

markus.georgi@fresenius.com

----------------------------------------

End of Note